TY - JOUR
T1 - Extracellular Vesicles as a Therapeutic Tool for Kidney Disease: Current Advances and Perspectives
AU - Corrêa, Raphael Rodrigues
AU - Juncosa, Estela Mancheño
AU - Masereeuw, Rosalinde
AU - Lindoso, Rafael Soares
N1 - Funding Information:
Funding: This work was supported by the partners of Regenerative Medicine Crossing Borders (Regmed XB). Powered by Health~Holland, Top Sector Life Sciences and Health; the Dutch Ministry of Education, Culture and Science; the Brazilian National Research Council (grant number 421916/2016-8); and the Carlos Filho Rio de Janeiro State Research Foundation (E-26/010.000981).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Extracellular vesicles (EVs) have been described as important mediators of cell communi-cation, regulating several physiological processes, including tissue recovery and regeneration. In the kidneys, EVs derived from stem cells have been shown to support tissue recovery in diverse disease models and have been considered an interesting alternative to cell therapy. For this purpose, however, several challenges remain to be overcome, such as the requirement of a high number of EVs for human therapy and the need for optimization of techniques for their isolation and characterization. Moreover, the kidney’s complexity and the pathological process to be treated require that EVs present a heterogeneous group of molecules to be delivered. In this review, we discuss the recent advances in the use of EVs as a therapeutic tool for kidney diseases. Moreover, we give an overview of the new technologies applied to improve EVs’ efficacy, such as novel methods of EV production and isolation by means of bioreactors and microfluidics, bioengineering the EV content and the use of alternative cell sources, including kidney organoids, to support their transfer to clinical applications.
AB - Extracellular vesicles (EVs) have been described as important mediators of cell communi-cation, regulating several physiological processes, including tissue recovery and regeneration. In the kidneys, EVs derived from stem cells have been shown to support tissue recovery in diverse disease models and have been considered an interesting alternative to cell therapy. For this purpose, however, several challenges remain to be overcome, such as the requirement of a high number of EVs for human therapy and the need for optimization of techniques for their isolation and characterization. Moreover, the kidney’s complexity and the pathological process to be treated require that EVs present a heterogeneous group of molecules to be delivered. In this review, we discuss the recent advances in the use of EVs as a therapeutic tool for kidney diseases. Moreover, we give an overview of the new technologies applied to improve EVs’ efficacy, such as novel methods of EV production and isolation by means of bioreactors and microfluidics, bioengineering the EV content and the use of alternative cell sources, including kidney organoids, to support their transfer to clinical applications.
KW - 3D culture
KW - Bioengineering vesicles
KW - Bioreactor
KW - Extracellular vesicles
KW - Isolation methods
KW - Kidney disease
KW - Stem cell
UR - http://www.scopus.com/inward/record.url?scp=85106616813&partnerID=8YFLogxK
U2 - 10.3390/ijms22115787
DO - 10.3390/ijms22115787
M3 - Review article
C2 - 34071399
SN - 1661-6596
VL - 22
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 11
M1 - 5787
ER -